Longevity research has moved decisively beyond single-compound investigation. The biology of ageing is now understood well enough that researchers are designing multi-compound protocols targeting different hallmarks of cellular ageing simultaneously — and the Epithalon + MOTS-c + NAD+ combination has emerged as the most mechanistically coherent and comprehensively evidenced longevity stack available for research in Australia in 2026.
Each compound targets a distinct and well-characterised axis of biological ageing. Together they address telomere maintenance, mitochondrial function, and NAD-dependent cellular repair — three of the most important and best-validated molecular drivers of age-related decline. Here is the complete scientific case for this combination.
The modern understanding of biological ageing identifies twelve interconnected hallmarks — molecular and cellular processes that progressively deteriorate with age and drive the functional decline associated with growing old. No single compound addresses all twelve. But the most productive research approach in 2026 targets multiple hallmarks simultaneously through mechanistically distinct compounds — covering more of the ageing biology simultaneously than any single-compound protocol can achieve.
The Longevity Stack targets three of the most important and tractable hallmarks:
Telomere attrition — addressed by Epithalon through telomerase activation via hTERT upregulation.
Mitochondrial dysfunction — addressed by MOTS-c through AMPK activation and mitochondrial biogenesis promotion.
NAD+ decline — addressed by NAD+ supplementation through direct restoration of the coenzyme that powers sirtuin and PARP enzyme systems central to DNA repair and metabolic regulation.
These three hallmarks are not independent. They interact and amplify each other — mitochondrial dysfunction accelerates telomere shortening through reactive oxygen species production; NAD+ decline impairs the sirtuin activity that regulates both mitochondrial function and DNA repair; telomere shortening triggers cellular senescence that further disrupts mitochondrial homeostasis. Targeting all three simultaneously addresses not just individual hallmarks but the interconnected network of ageing biology they form.
Epithalon is a synthetic tetrapeptide with the sequence Ala-Glu-Asp-Gly, derived from Epithalamin — a natural pineal gland peptide first characterised by Professor Vladimir Khavinson’s team in Russia. Its defining mechanism is activation of telomerase through upregulation of the hTERT gene — the catalytic subunit responsible for adding telomeric repeats to chromosome ends and reversing the telomere shortening that progressively limits cellular replicative capacity with age.
Telomeres shorten as you age, leading to cellular dysfunction, DNA damage, and ageing. Research suggests Epithalon may activate the enzyme telomerase, which helps rebuild telomeres. Longer telomeres are associated with better cellular longevity and a lower risk of age-related diseases.
Beyond telomerase activation, Epithalon restores melatonin secretion rhythms in ageing subjects — addressing the age-related decline in pineal gland function that contributes to disrupted circadian biology, impaired sleep architecture, and the downstream metabolic and immune consequences of chronic circadian disruption. Epithalon also demonstrates antioxidant activity — reducing the oxidative stress that is one of the primary drivers of accelerated telomere shortening, creating a mechanistic synergy between its direct telomerase-activating effects and its oxidative stress reduction.
In the Longevity Stack context: Epithalon provides the telomere-level foundation — addressing the molecular clock that limits cellular replicative lifespan and the circadian biology that regulates the entire organism’s temporal coordination. It operates on the longest timescale of the three compounds, with effects that accumulate over weeks and months of research protocols rather than producing acute measurable changes.
MOTS-c is a 16-amino acid peptide encoded directly within mitochondrial DNA — one of a small and recently characterised class of mitochondria-derived peptides that are reshaping understanding of how mitochondria communicate metabolic status to the rest of the cell and organism. Its primary mechanism is activation of AMPK — AMP-activated protein kinase — the body’s cellular energy sensor and metabolic master switch.
AMPK activation produces a cascade of effects directly relevant to longevity research:
Mitochondrial biogenesis: AMPK activates PGC-1α — the master regulator of mitochondrial production — stimulating the creation of new mitochondria to replace those damaged by age-related dysfunction. Mitochondrial density and function decline with age; MOTS-c’s capacity to drive mitochondrial biogenesis addresses this decline at its source.
mTOR inhibition: AMPK inhibits mTOR signalling — a pathway associated with accelerated ageing when chronically overactive. The AMPK/mTOR balance is one of the central regulatory axes of cellular longevity biology, placing MOTS-c’s AMPK-activating properties at the heart of the molecular longevity research agenda.
Autophagy induction: Through mTOR inhibition and direct pathway activation, AMPK promotes autophagy — the cellular self-cleaning process by which damaged proteins and organelles are removed. Declining autophagy is one of the hallmarks of cellular ageing; MOTS-c’s capacity to restore autophagic activity connects its metabolic profile to the broader biology of cellular maintenance.
Cellular senescence prevention: 2025 research demonstrated that MOTS-c prevents pancreatic islet cell senescence — the process by which cells lose function and enter a pro-inflammatory senescent state. Cellular senescence accumulation is now recognised as a primary driver of age-related tissue dysfunction; MOTS-c’s anti-senescence effects represent a direct intervention in this hallmark.
Mitochondrial DNA integrity restoration: 2025 research demonstrated restoration of mitochondrial DNA integrity in ageing cells following MOTS-c treatment — addressing one of the most fundamental mechanisms of mitochondrial dysfunction with age, and creating a mechanistic bridge to Epithalon’s DNA-level effects on telomere integrity.
In the Longevity Stack context: MOTS-c provides the mitochondrial foundation — restoring the energy production capacity, autophagic maintenance, and metabolic flexibility that decline at the core of every ageing cell. It operates at the intracellular level, addressing the bioenergetic dimension of cellular ageing that Epithalon’s telomere and circadian mechanisms do not directly target.
NAD+ (nicotinamide adenine dinucleotide) is not a peptide — it is a coenzyme present in every living cell and essential to hundreds of metabolic reactions. Its inclusion in the Longevity Stack reflects the fact that NAD+ decline is one of the most well-documented and consequential molecular changes of biological ageing — and one of the most directly addressable through supplementation research.
NAD+ levels decline by approximately 50% between the ages of 40 and 60 in human tissue — a decline that compromises the activity of two critical enzyme families:
Sirtuins: NAD-dependent deacetylases that regulate gene expression, DNA repair, mitochondrial biogenesis, inflammation, and metabolic function. Sirtuin activity declines proportionally with NAD+ availability — meaning NAD+ decline effectively impairs the entire sirtuin-regulated longevity programme simultaneously.
PARPs (Poly ADP-ribose polymerases): NAD-consuming enzymes that repair DNA strand breaks. PARP activity competes with sirtuin activity for the available NAD+ pool — meaning that increased DNA damage with age (which activates PARPs) further depletes NAD+ available to sirtuins, creating a vicious cycle of declining repair capacity and declining sirtuin function.
The research case for NAD+ in longevity protocols is built on this dual sirtuin and PARP dependence — restoring NAD+ levels restores the enzymatic capacity for DNA repair and sirtuin-regulated metabolic regulation simultaneously.
In the Longevity Stack context: NAD+ provides the energetic and enzymatic substrate that makes the other two compounds’ mechanisms more effective. MOTS-c’s mitochondrial biogenesis requires NAD+ for the metabolic reactions that power new mitochondrial function. Epithalon’s telomerase activation and the DNA repair that maintains telomere integrity both depend on adequate PARP and sirtuin activity — which requires NAD+. The three compounds are therefore not just mechanistically complementary but metabolically interdependent.
The scientific case for combining Epithalon, MOTS-c, and NAD+ is stronger than the sum of the individual compounds’ profiles — because the three targets they address are not independent hallmarks but interconnected nodes in a single network of cellular ageing biology.
The mitochondria-telomere connection: Mitochondrial dysfunction — addressed by MOTS-c — produces reactive oxygen species that accelerate telomere shortening. By improving mitochondrial function and reducing oxidative stress, MOTS-c reduces one of the primary drivers of the telomere attrition that Epithalon targets directly. The two compounds therefore work synergistically on telomere biology — Epithalon through direct telomerase activation, MOTS-c through reducing the oxidative burden that drives telomere loss.
The NAD-sirtuin-mitochondria connection: Sirtuin activation — enabled by NAD+ restoration — directly regulates mitochondrial biogenesis and function through SIRT1 and SIRT3 activity. This means NAD+ restoration amplifies MOTS-c’s mitochondrial effects — the two working the same target from different angles. MOTS-c activates AMPK which drives PGC-1α and mitochondrial biogenesis. NAD+ activates sirtuins which also drive PGC-1α through SIRT1 deacetylation. Both pathways converge on the same mitochondrial biogenesis programme.
The DNA repair connection: Epithalon’s telomerase activation and the maintenance of telomere integrity both require active DNA repair machinery — specifically PARP-mediated strand break repair. NAD+ restoration ensures that PARP has adequate substrate to maintain this repair activity, directly supporting the genomic stability that Epithalon’s telomere work requires.
The senescence connection: All three compounds address cellular senescence through different mechanisms. Epithalon prevents the telomere shortening that triggers senescence. MOTS-c directly prevents cellular senescence as demonstrated in 2025 research. NAD+ restores sirtuin activity that suppresses the senescence-associated secretory phenotype (SASP) — the pro-inflammatory signalling of senescent cells that damages surrounding tissue. Together they address senescence at the trigger, the process, and the downstream inflammatory consequences.
For Australian researchers designing Longevity Stack protocols, several considerations are important:
Temporal sequencing: The three compounds operate on different timescales. NAD+ effects on cellular metabolism are relatively acute — measurable within days to weeks. MOTS-c’s mitochondrial effects develop over weeks of consistent administration. Epithalon’s telomere effects operate on the longest timescale — accumulating over months of protocol and requiring extended study designs to capture meaningfully.
Biomarker selection: Comprehensive longevity stack research requires biomarker panels that can track effects across all three target systems simultaneously — telomere length measurements, mitochondrial function assays, NAD+ tissue levels, and cellular senescence markers.
Stagger cycling: The longevity combination of Epithalon, MOTS-c, and NAD+ is often studied with staggered cycling — so not all compounds run simultaneously throughout the entire protocol — allowing researchers to isolate individual compound contributions within a combination study design.
Companion compounds: The Longevity Stack is frequently extended with SS-31 for additional mitochondrial membrane support, and GHK-Cu for the gene-regulatory and collagen synthesis dimensions of tissue ageing that Epithalon, MOTS-c, and NAD+ do not directly address.
Australian Peptides supplies MOTS-c, GHK-Cu, BPC-157, TB-500, R3TA, and proprietary GLOW and KLOW research stacks for research purposes with HPLC-verified purity documentation and domestic Australian dispatch. Browse our full catalogue for all your longevity and recovery research needs.
New batch COAs and restock alerts, sent when they happen.
Need more information about Australian Peptides? Get in contact with us via the email below and Australian Peptides will assist you promptly.
Include your name and a relevant subject line.
Every batch we publish a third-party certificate of analysis. Get told when a new one lands, and when a sold-out peptide is back.
